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Abstract— In this paper, we present an optical diagnostic assay 
consisting of a mixture of environmental-sensitive fluorescent 
dyes combined with multivariate data analysis for quantitative 
and qualitative examination of biological and clinical samples. 
The performance of the assay is based on the analysis of spectrum 
of the selected fluorescent dyes with the operational principle 
similar to electronic nose and electronic tongue systems. This 
approach has been successfully applied for monitoring of growing 
cell cultures and identification of gastrointestinal diseases in 
humans. 
 
Index Terms— chemometrics, clinical applications, 
fluorescence dyes, optical diagnosis. 
I. INTRODUCTION 
INCE the last decade the research associated with the 
development of new sensor assays to detect multiple 
analytes has been growing intensively [1-3]. The use of such 
an intelligent device with the capability of accurate and 
reliable diagnosis could help to decrease probability of harm, 
minimize clinical intervention, costs of medical treatment and 
as a consequence improve long-term public health. This 
requires new developments and implementation of suitable 
indicators to estimate potential risk factors and their effects on 
health, identification of early symptoms of diseases or 
monitoring the progress of treatment [4, 5]. 
Current trends in the development of sensing technologies 
mimic perception of mammalian smell and taste (schematically 
shown in Fig. 1a). Known as electronic noses (e-noses) and 
tongues (e-tongues), these techniques [6, 7] are based on the 
'smelling/tasting' array of cross-sensitive chemical receptors 
and interpretation of detected composite signals with suitable 
statistical methods [8, 9] (see Fig. 1b). The specificity of such 
a methodology is related to the pattern recognition in response 
to signals produced by interactions of the sample with all 
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sensing elements [10, 11]. The obtained patterns are unique to 
particular conditions and therefore can be considered similar 
as the fingerprints. 
The analytical capability of such an approach is less likely 
to lie in the measurements of analytes’ concentrations than in 
profiling the chemical or biological processes and qualitative 
sample analysis.
 
Although both e-nose and e-tongue 
technologies are currently commercially available, they suffer 
from significant limitations, such as poor stability, limited 
selectivity, low reproducibility, demand for frequent 
calibration, complexity of generated information, and high 
fabrication costs of sensor arrays [6,12]. 
Lately there has been a surge of attention to optical 
diagnostics, especially in the field of real-time non-invasive in 
vivo detection [13]. This is explained by the facts that optical 
techniques are often non-destructive, do not require physical 
contact with a sample during analysis and enable rapid 
response [14,15]. They are able to provide information at the 
molecular level through tissues and living organs originating 
from both animals and humans. Light can also be used as a 
tool for manipulating or modifying living cells and can be 
focused at a tiny spot, which allows precise localised and 
minimal invasive treatment [16]. By providing more effective, 
cheaper and easy accessible service, biophotonics and optical 
diagnostic technology can have a huge and crucial impact on 
clinical practice. 
Recently we described a fluorescence-based assay with the 
operating principle similar to e-noses and e-tongues used for 
simultaneous measurements of several physicochemical 
parameters [17]. Those preliminary experiments have been 
performed to investigate the analytical capability of the 
proposed assay and validate its potential for quantitative 
analysis of samples. Additionally, previous publication 
includes the details on the methodology and data evaluation. A 
schematic illustration of the concept of optical/fluorescent 
assay is shown in Fig. 1c. The mixture of five fluorescent dyes 
interacts with the sample and generates excitation-emission 
matrix (EEM) fluorescence spectra (Fig. 2) distinctive for 
biochemical or medical conditions. 
EEMs are generated by passing white light (typically from a 
Xe source) through an excitation polychromator which splits 
the light into different wavelengths at a pre-determined range 
which then irradiate the sample in the cuvette. The 
fluorescence light emitted by the sample passes through an 
emission polychromator which also splits the light into









Fig. 1. Schematic representation of sensing systems: (a) human olfactory system, (b) electronic analogue and (c) optical/fluorescence analogue [17]. 
 
different wavelengths from which the split light is captured on 
a charge-coupled device (CCD) camera, thus generating an 
image or fluorescence profile as shown in Fig. 2. Using 
chemometric approaches these patterns are further analyzed 
and the optical signal is transferred into analytical 
characteristics of the samples. Additionally, for the minimum 
interference with biological samples, selected fluorescent dyes 
are responsive in the VIS-NIR range. 
 
Fig. 2. 3D color mapped surface of the excitation-emission spectral pattern 
for selected 5 fluorescent dyes: Dye 1 is 8-hydroxypyrene-1’,3,6-trisulfonic 
acid, Dye 2 is Oregon green 514, Dye 3 is Rhodamine B, Dye 4 is Tris(4,7-
diphenyl-1,10-phenanthroline) ruthenium dichloride, Dye 5 is Thionin acetate 
[17]. 
In the current study we investigate the potential of the 
technique developed in [17] for qualitative examination of 
biological and clinical samples. 
 The feasibility of this approach has been tested for 
monitoring development phases of growing bacterial cultures 
and for analysis of urine samples from healthy volunteers and 
patients diagnosed with gastrointestinal diseases. 
In the first issue we take into account that certain types of 
bacteria, fungi, viruses or parasites have significant impact on 
human life considering their beneficial or harmful effects. 
Therefore, controlling the growth of microorganisms is 
necessary for many practical reasons including medicine, 
prevention or treatments of diseases, production of drugs, etc. 
This involves the identification of the phases of microbial 
growth to inhibit the process or recognize and learn favorable 
environmental conditions, which they need to live and 
reproduce. 
The second test was performed on human urine samples for 
recognition of three gastro-intestinal diseases (irritable bowel 
syndrome, Crohn’s disease and ulcerative colitis). They are 
currently serious public health problems, which have been 
forecasted to further increase in most countries around the 
world [18, 19]. The identification of the symptoms, early 
diagnosis and treatment of these diseases is still challenging 
because the etiology and factors causing these complex 
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disorders are yet not well known. Therefore, their mechanisms 
are difficult to explain, various types difficult to discriminate 
and therapeutic targets hard to identify [20, 21]. Typically, 
their diagnosis involves many analytical tests which are often 
costly and invasive. Therefore, it is of the great importance to 
search for the suitable and sensitive method for controlling 
gastrointestinal microbiota and early detection of dangerous 
pathogens [22]. 
II. MATERIALS AND METHODS 
The assay composed of five commercially available and 
inexpensive fluorescent dyes has been successfully developed 
for measurements of pH, temperature, dissolved oxygen and 
ionic strength of a solution (given by a buffer concentration) 
[17]. The results obtained have demonstrated, with high 
accuracy, quick, simultaneous identification and calculation of 
several physicochemical parameters (see Table I). Analytical 
performance of the assay was demonstrated with relatively low 
root means square error (RMSE), which describes the quality 
of fitting of a regression model. 
 
TABLE I 
 PERFORMANCE OF FLUORESCENT DYES ASSAY 





Oregon Green 514 
5 - 9 0.004 
2 temperature 
[oC] 
Rhodamine B 25 - 40  0.437 





0 - 21.6 0.049 
4 buffer concentration 
[mM] 
8-Hydroxypyrene- 
1’,3,6 - trisulfonic acid 
5 - 150 6.818 
 
A. Composition of dyes mixture 
The mixture of fluorescent dyes were prepared as a stock 
solution of following dyes: 0.15 mM 8-Hydroxypyrene-1’,3,6-
trisulfonic acid, 0.1 mM Rhodamine B, 2 mM Thionin acetate, 
0.025 mM Oregon Green 514, 6 mM Tris (4,7 – diphenyl - 
1,10 - phenanthroline) ruthenium dichloride. Solutions of dyes 
were prepared in deionized water and stored in ~5 ºC, covered 
with aluminum foil to protect them from light. The 200 µl of 
each water/dye stock solutions were mixed together and used 
in further experiments. 
B. Samples preparation 
The bacterial strain used in the experiment was Escherichia 
coli (JM 83) provided by Cranfield University (UK). Bacteria 
were recovered from frozen state by growing them in a Miller 
LB broth (Fluka Biochemica, Cat No.1.10285), solution of 
12.5 g of the medium in 0.5 L of Milli-Q water, overnight at 
37 ºC and subcultured. The bacteria colonies were transferred 
into centrifuge tubes filled with 20 ml of liquid medium and 
incubated for 60 hours at 37 ºC [23]. The tubes with bacteria 
cells were collected at different intervals and centrifuged at 
2800 rpm for 20 min. The supernatant was filtered through a 
0.22 µm filters and 3 ml of the filtrate were transferred into 4 
ml quartz cuvettes. The optical/fluorescent assay was then 
applied to supernatants taken from suspensions of growing 
bacteria. Control fluorescent measurements were performed 
using samples without growing bacteria.  Additionally, 
bacterial growth was monitored by measuring the absorption 
of the suspensions [24]. 
Further experiments have been performed with urine 
samples obtained from healthy volunteers (CTR) and patients 
diagnosed with Crohn's disease (CD), ulcerative colitis (UC) 
and irritable bowel syndrome (IBS). All volunteers were given 
information, consent forms to read and sign, and a 
questionnaire, which provide details on their diet, exercise, 
sleep, medication and general health. The samples, provided 
by Addenbrookes Hospital (UK), have been obtained prior to 
any medical treatment and/or conservation. They have been 
stored at -80 ºC to maintain sample integrity. Before the 
measurements each sample was defrosted, centrifuged at 2800 
rpm for 20 minutes and filtrated through 0.45 µm glass fiber 
filters. The mixture of fluorescent dyes was added into this 
supernatant, and then measured. 
C. Instrumentation 
The measurements of fluorescence intensity have been 
performed using three-dimensional spectrofluorimeter Jobin 
Yvon – SPEX FL-3D (Instruments SA, Stanmore, Middlesex, 
UK) at 0.5 s of time exposure. The spectra have been recorded 
over a range of excitation (74-691 nm) and emission (227-724 
nm) wavelengths. The range of wavelengths was based on the 
technical specification of the spectrofluorometer. The 
fluorescence measurements were performed using quartz 
cuvettes with stoppers and a light path of 10 mm. 
Absorption spectra of bacteria suspensions at different 
growing phases were measured with Spectrometer (UVPC 
2100, Shimadzu, Japan) at 550 nm. 
D. Data evaluation 
The changes in fluorescent patterns (see an example in Fig. 
2) caused by interactions with the dyes surrounding media 
have been analyzed using an artificial neural network (ANN). 
ANNs were implemented in MATLAB (version 7.3.0, 
MathWorks Inc., 2006) using the Neural Network Toolbox 
(version 5.0.1) and trained on the data patterns of samples of 
known identity (45 samples with known time of bacteria 
growth from 0 to 60 hours) using Bayesian back-propagation 
of errors [25]. Once the ANN was trained, the approach was 
applied for evaluation of 18 unseen samples. Based on 
learning experience, the network was capable of identifying 
unknown fluorescent fingerprints and predicting outputs 
(identifying different test solutions). 
The total number of urine samples provided was limited to 
32. We admit that this number is small yet for statistical 
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purposes it is suitable to generate preliminary results leading to 
a proof of concept. Table II summarizes the sample 
distribution between the disease states. In order to classify the 
three gastrointestinal diseases pertaining to the urine samples 
via their EEM spectra, two approaches were undertaken. 
  
TABLE II 














9 11 6 6 
 
The first involved performing principal components analysis 
(PCA) [25] on each sample’s EEM spectrum in order to attain 
the most influential emission profiles. This was achieved by 
taking, for each sample, the loadings profile of the first 
principal component (PC1) which is generated from the 
decomposition of the respective EEM spectrum. The PC1 
loadings profile is taken because it will have a high percentage 
of variance and have no contribution from noise within the 
EEM spectrum. The collection of profiles were inputs for the 
ANN probability network [26] to classify each of the three 
diseases from the healthy controls by assigning class values to 
the states: 1 for healthy; 2 for disease. Leave-one-out cross-
validation (LOO-CV) permitted each sample to be classified 
leading to an overall success of classification. In order to 
perform a thorough analysis, and thus to ascertain the best 
results, different scaling techniques were employed such as 
mean-centering, auto-scaling and range-scaling. Each have 
their own merits: mean-centering removes any offset from the 
data originating for example from instrumental drift; auto-
scaling permits the analysis of the data by correlation and not 
covariance; range-scaling make all the samples equally 
important therefore biological activity dominates.  The linear 
classification technique of partial least squares discriminant 
analysis (PLSDA) [27] was also employed for comparison 
against ANN. The technique of PLSDA attempts to maximize 
the covariance between the classification (healthy vs disease) 
and the loadings profiles. 
The second approach involved the use of a multi-way 
technique called parallel factor (PARAFAC) analysis [28]. It 
is a multi-way extension of PCA and thus permits data 
reduction of a data cube (collection of EEMs) into a scores 
matrix and two loadings matrices: the first containing profiles 
pertaining to excitation wavelengths; the second containing 
profiles pertaining to emission wavelengths. The key 
advantage with this technique is that given the correct number 
of components have been selected, the pure fluorescence 
emission spectra for each dye can be captured within the 
PARAFAC loadings [29]. The loadings corresponding to the 
emission spectra were combined with the scores to reproduce 
the sample matrix in which the number of rows corresponds to 
the number of samples and the number of columns to the 
emission wavelength range. This matrix formed the input 
parameters for PLSDA and the ANN probability network. 
Classification was performed as described above. 
Finally, in order to ensure that the results were valid, a 
Monte Carlo simulation was performed [30]. This involves 
generating random class values for each sample and then 
classifying via the leave-one-out cross-validation (LOO-CV) 
method. The number of runs was set to 500. This is to 
guarantee a normal distribution is attained. If the overall 
classified result is beyond the 95% confidence limit, then that 
result can be deemed valid. 
III. RESULTS 
In the analysis of bacteria growth the mixture of dyes was 
added to supernatants taken from suspensions of growing 
microrganisms. Samples were collected at different intervals of 
time. During their growth the concentration of nutrients, 
oxygen and pH were changing. These reflected in the 
modification of dyes spectra which were further analyzed by 
ANN. Bacterial growth was monitored by measuring the 
absorption of the suspensions. Additionally, control 
measurements were performed using samples consisting of the 
mixture of fluorescence dyes in solutions of only the medium 
(LB broth), without growing cells. They were kept in the same 
condition as diagnosed samples. The results for control 
measurements showed no changes in fluorescence signal, 
whereas the changes in fluorescence caused by the presence of 
bacteria have been clearly identified. 
The results of ANN predictions are presented in Fig. 3. The 
graph illustrates the correlation between real (measured) time 
of growth of bacteria culture (x axis), and the time predicted 
by ANN (y axis). Circles (○) indicate the mean values of data 
points of the network prediction and error bars indicate 
standard deviation.  
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Fig. 3. Correlation between the time of bacterial growth measured 
experimentally and predicted by ANN: circles (○) indicate mean values of 
data points of ANN simulations: solid line (  ) shows the best linear fit and 
the line ( – • – ) presents ideal response of ANN with zero error. Error bars 
indicate standard deviation. 
 
These results demonstrate capability of the technique to 
identify detected fluorescent fingerprints and predict outputs. 
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The RMSE is 6.412 and indicates very accurate prediction and 
the potential of the dye assay application to analyze biological 
samples. 
Classification of the urine samples (Fig. 4) shows great 
promise particularly when performed with artificial neural 
networks (ANNs) and in both cases, outperform the linear 
approach of partial least squares discriminant analysis 
(PLSDA). Fig. 4 also shows that, overall, the ANN probability 
network has performed better than PLSDA. However, with 
regards to PCA, the sensitivity of PLSDA is slightly superior 
to that of ANN (Fig. 4a and 4b) which means that it can 
distinguish the respective disease better with the exception of 




Fig. 4. Comparison of the PLSDA (a and c) against the ANN probability 
network (b and d) to discriminate the three diseases from the healthy controls 
in terms of % Overall*, % Specificity** and % Sensitivity*** after 
application of PCA (a and b) and PARAFAC (c and d) to each EEM. 
*Overall means the overall success of discrimination; **Specificity 
represents the number of true negatives (e.g. healthy samples). If the 
percentage of true negatives was 90% (90 out of 100 healthy samples were 
classified correctly) then there would be 10% false positives (10 out of 100 
healthy samples incorrectly classified, i.e. classed as diseased); 
***Sensitivity represents the number of true positives (e.g. diseased 
samples). If the percentage of true positives were 95% (95 out of 100 diseased 
samples correctly classified), then there would be 5% false negatives (5 out of 
100 diseased samples incorrectly classified, i.e. classed as healthy). 
 
However in terms of specificity we observe 100% which 
implies that the healthy control can be completely 
distinguished from the diseased samples. With regards to 
PARAFAC (Fig. 4c and 4d) the ANN probability network has 
performed better than PLSDA but also has resulted in a better 
outcome than the application of PCA. On this occasion, the 
sensitivity pertaining to UC in PLSDA (100%) is better than 
ANN (83%) yet the corresponding specificity is much worse 
(Fig. 4c). 
In order to confirm that the results are indeed valid, Monte 
Carlo simulations were performed. In this context, the word 
“simulation” does not refer to a hypothetical situation 
(emulation of reality) but the fact that repeated sampling is 
performed. In this case, the classification vector is randomly 
generated, and then used in the classification procedure with 
either PLSDA or ANN. 
Fig. 5 shows two examples of plots attained which affirm 
that the results are valid. Both plots (Fig. 5a and 5b) show a 
normal distribution and that the overall percent classified is 
beyond the 95% confidence limit, in other words the results 
are significant and not due to chance. The reason for the lack 
of results, e.g. ~42% and ~68% in Fig. 5a and ~53% in Fig. 
5b, is due to the fact there is an odd number of samples in the 




Fig. 5. Monte Carlo simulations applied to the urine samples in which very 
good overall classifications were attained for PCA (a) and PARAFAC (b). 
 
IV. DISCUSSION 
These promising results indicate that it is possible to use the 
fluorescence signals of a dye assay combined with an artificial 
neural network (ANN) model in the determination of bacterial 
presence and their growth phases. This would be helpful for 
analysis of the quality of clinical, pharmaceutical or 
biomedical samples. Further analysis can be improved by 
investigation of specific factors which affect bacteria growth, 
such as pH, oxygen, salt, sugars or nutrients concentration. 
Usually, these parameters are optimal for one strain but they 
tend to vary for others. They also can change the natural 
environment and affect the growth of particular strain of 
microorganisms. Therefore it is important to know the actual 
effects of single factors on the growth of microbial. The 
current results indicate that it is possible to control the growth 
rate of microorganisms implying that in the future it will be 
comprehensively possible to inhibit unwanted strains from 
growing such as human pathogenic bacteria. Conversely, it can 
lead to the improvement of the development of the beneficial 
strains once the impact of certain factors on their growth is 
better understood. 
The work here has also demonstrated that ANNs can be 
employed as a classification tool to distinguish three 
gastrointestinal diseases (irritable bowel syndrome, Crohn’s 
disease, and ulcerative colitis) from healthy controls with 
extremely good overall accuracies of >90%. ANNs also 
performed better than partial least squares discriminant 
analysis (PLSDA). This can be partly attributed to the fact that 
PLSDA can only model linear relationships where as ANNs 
are able to model both linear and non-linear relationships [26]. 
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Furthermore, classification via PLSDA has produced very 
good sensitivities but poor specificities which imply that many 
false positives were predicted (Fig. 4c). In contrast, the 
classification via ANN has resulted in high sensitivities and 
specificities, especially for Crohn’s disease (CD) at 92% and 
100% respectively (Fig. 4d). 
However the success in distinguishing the diseases from the 
controls is also attributable to the data pre-treatment, that is in 
the employment of parallel factor (PARAFAC) analysis to 
extract the pure emission profiles from the EEM spectra – a 
major advantage of PARAFAC provided that the correct 
number of components are selected [29]. This was shown to be 
better than using principal components analysis (PCA). This is 
because PCA only focused on the EEM of one sample 
therefore a PCA loading (PC1) was generated for each sample. 
However, PARAFAC was able to act on all of the EEMs 
simultaneously, i.e. across all the samples, therefore revealing 
other trends and characteristics within the data that cannot be 
detected by PCA alone. It must be stated that PCA is not a 
classification technique; it is exploratory. In this capacity it 
acts as a data reduction technique with the aim of removing 
noise. PC1 is thus used because it contains the emission profile 
that will have captured the most variance in the data and have 
zero contributions from noise. 
The success of the classification of the three diseases against 
the control is fortified by the application of the Monte Carlo 
simulation [30]. This has statistically demonstrated that the 
respective overall accuracies attained are not due to chance 
(Fig. 5). This also implies that the respective models generated 
have good accuracy. It is therefore feasible to infer that there 
are significant and distinctive characteristics contained within 
the excitation-emission matrix (EEM) spectra (e.g. Fig. 2) to 
permit the classification of the diseased samples. 
Leave-one-out cross validation (LOO-CV) is a thorough yet 
time-consuming procedure, particularly if there are a large 
number of samples (e.g. in excess of 100). Other forms of 
cross-validation exist such as venetian blinds cross validation 
(VB-CV) and block cross validation (B-CV) [30]. The former 
involves omitting, for example the odd-numbered samples, 
building a model with the even-numbered samples then 
classifying the odd-numbered samples; the next iteration 
would involve omitting the even-numbered samples, etc. Other 
permutations could also be implemented. B-CV is more 
similar to LOO-CV but instead of omitting one sample, omits 
for example 10 consecutive samples and builds a model with 
the remaining samples.  These work faster than LOO-CV yet 
are not as accurate. 
In recent years the technique of bootstrapping has become 
commonly employed [30]. A specified number of samples are 
selected randomly from the dataset to form a validation set. 
The remaining samples thus make up the bootstrap set. The 
latter is randomly split into a training and test set. A model is 
created from the training set then the test set is classified. This 
is repeated N times, e.g. where N could be 250. The model that 
resulted in the best classification is used to classify the 
validation set from which the accuracy and performance are 
assessed. Given that accuracy tends to be better, bootstrapping 
can however be computationally intensive. For this work, the 
low number of samples present in each subset (as shown in 
Table II) did not permit its use therefore LOO-CV was 
employed. 
Although the total number of samples used in this study are 
low (32), the study has illustrated the potential of this 
proposed method. The next phase of the work would involve 
substantially increasing the number of samples, for example in 
excess of 100. This would lead to improved clinical relevance 
since every patient or healthy volunteer will have different 
characteristic responses as indicated by the metabolites 
contained in their urine. Furthermore, the ability to be able to 
distinguish the diseased samples from each other, for example, 
a “one-against-all” approach such as classifying irritable bowel 
syndrome in the presence of healthy controls, Crohn’s disease 
and ulcerative colitis, should also be investigated. Finally, 
making use of the metadata collected via the questionnaire 
(diet, lifestyle, medication, etc) could also be incorporated into 
the classification model.  
V. CONCLUSIONS 
In this study, we demonstrated an optical form of e-nose and 
e-tongue, which offers a promising alternative to 
electrochemical systems providing highly sensitive, easy and 
inexpensive measurements where no reference signal is 
needed. The system also gives a possibility of remote sensing 
and further assay miniaturization. Potential of the proposed 
analytical tool is wide and diverse and can have great impact 
on a variety of applications including non-invasive diagnostics 
of tissues, cosmetics testing, early warning of ultraviolet 
radiation abuse, general health monitoring, therapeutic 
management, fundamental physiological investigations and 
disease diagnosis. 
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